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Abstract The purpose of this study was to estimate the
influence of adjuvant radiotherapy for primary breast can-
cer (BC) on the risk of contralateral BC (CBC) in BRCA1
or BRCA2 (BRCA1/2) mutation carriers, with special
attention to patients irradiated at age younger than
40 years. Additionally, tendencies in locoregional treat-
ments and rates of contralateral risk-reducing mastectomy
over time were explored. In this retrospective cohort study,
691 BRCA1/2-associated BC patients treated between 1980
and 2013 were followed from diagnosis until CBC or
censoring event including ipsilateral BC recurrence, distant
metastasis, contralateral risk-reducing mastectomy, other
invasive cancer diagnosis, death, or loss to follow up.
Hazard ratios (HR) for CBC associated with radiotherapy
were estimated using Cox regression. Median follow-up
time was 8.6 years [range 0.3–34.3 years]. No association
between radiotherapy for primary BC and risk of CBC was
found, neither in the total population (HR 0.82, 95 % CI
0.45–1.49) nor in the subgroup of patients younger than
40 years at primary diagnosis (HR 1.36, 95 % CI
0.60–3.09). During follow-up, the number of patients at
risk decreased substantially since a large proportion of
patients were censored after contralateral risk-reducing
mastectomy or BC recurrence. Over the years, increasing
preference for mastectomy without radiotherapy compared
to breast-conserving surgery with radiotherapy was found
ranging from less than 30 % in 1995 to almost 50 % after
2010. The rate of contralateral risk-reducing mastectomy
increased over the years from less than 40 % in 1995 to
more than 60 % after 2010. In this cohort of BRCA1/2-
associated BC patients, no association between radiother-
apy for primary BC and risk of CBC was observed in the
total group, nor in the patients irradiated before the age of
40 years. The number of patients at risk after 10 and
15 years of follow-up, however, was too small to defini-
tively exclude harmful effects of adjuvant radiotherapy.
Keywords Radiotherapy  BRCA mutation  Contralateral
breast cancer  Risk-reducing mastectomy  Breast-
conserving surgery
Introduction
Both normal breast tissue and breast cancer cells are sen-
sitive to ionizing radiation. Although adjuvant radiotherapy
for early breast cancer (BC) reduces the risk of local
recurrence and improves BC-specific survival [1, 2], it also
leads to a low-dose scatter radiation to the surrounding
healthy tissue with potentially carcinogenic effects. In
sporadic BC patients, adjuvant radiotherapy has been
associated with an increased risk of contralateral breast
cancer (CBC), although only among women younger than
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45 years at primary BC diagnosis and after a latency period
of at least 10–15 years [3–6].
The vulnerability of cells for ionizing radiation largely
depends on the rate of cell proliferation, the total dose of
radiation, the fractionation scheme, and the capability of
the cells to repair DNA damage [7]. Younger patients have
higher breast cell proliferation (in particular during pub-
erty, adolescence, and pregnancy) and thus increased DNA
synthesis that might render breast tissue particularly sus-
ceptible to the carcinogenic effects of radiation [8, 9]. The
capacity to repair DNA damage might substantially differ
between BC patients, in particular when considering
patients with or without a BRCA1 or BRCA2 (BRCA1/2)
mutation.
BRCA1/2-associated BC is characterized by homolo-
gous recombination deficiency, leading to inadequate
repair of double-strand DNA breaks [10, 11]. Ionizing
radiation can cause cell damage by induction of double-
strand DNA breaks. This has led to the hypothesis that
adjuvant radiotherapy administered for BRCA1/2-associ-
ated BC might be more effective than radiotherapy
administered for sporadic BC. On the contrary, surrounding
healthy breast tissue among BC patients with a BRCA1/2
mutation might be more vulnerable to the deleterious
effects of adjuvant radiotherapy, including the develop-
ment of a CBC, compared to those without a BRCA1/2
mutation.
In unaffected BRCA1/2 mutation carriers, exposure to
low cumulative doses of diagnostic radiation (including
screening mammography) at young age (\30 years) has
been reported to be associated with an increased risk of
BC, with a clear dose–effect relationship [12] compared to
no exposure to diagnostic radiation. The possible carcino-
genic effect of scatter ionizing radiation after adjuvant
radiotherapy on the contralateral breast in BRCA1/2-asso-
ciated BC patients, however, is not clear. Although a
number of studies addressed this question, all these studies
are compromised by a short duration of follow-up and the
lack of subgroup analyses regarding young BC patients.
[13–15]. Knowledge about the possibly increased risk of
CBC by radiotherapy might be of great importance for
optimal shared decision making regarding mastectomy
without radiotherapy versus breast-conserving surgery
including radiotherapy at primary BC diagnosis.
We therefore studied the impact of radiotherapy on the
risk of CBC among BRCA1/2-associated BC patients in a
retrospective cohort study, with special attention to patients
younger than 40 years at primary BC diagnosis. Since over
the years an increasing proportion of BRCA1/2 mutation
carriers after developing BC seems to opt for bilateral
mastectomy instead of unilateral mastectomy or breast-
conserving treatment with radiotherapy [16], we also
explored potential tendencies in locoregional treatments
and the rates of contralateral risk-reducing mastectomy
over the past decades.
Methods
Patient selection
From the Rotterdam Family Cancer Clinic database, we
extracted all female patients with early stage BC
(n = 2,268). From this population, we selected proven or
obligate BRCA1 or BRCA2 mutation carriers, treated at the
Erasmus MC Cancer Institute. Patients diagnosed from
January 1st 1980, corresponding to the start of linear
accelerators use for adjuvant breast radiotherapy at the
Erasmus MC, to January 1st 2013 were included
(n = 790). Time of observation ended at April 1st 2014.
Patients with less than 3 months of follow-up were
excluded (n = 52; see statistical analysis). Patients who
were treated with breast/chest wall radiotherapy or sys-
temic anticancer therapy because of another invasive
malignancy, either prior or synchronous to the primary BC,
were excluded (n = 16). Patients who had synchronous
bilateral BC and received bilateral radiation therapy or
mastectomy (n = 31) were also excluded, leaving a total of
691 patients available for the analyses.
For the eligible patients, data on primary BC and CBC
characteristics (type of histology, differentiation grade,
estrogen receptor (ER) status, progesterone receptor (PR)
status, HER2 status, and stage) and primary BC therapy
(surgery, radiotherapy, chemotherapy, and/or endocrine
therapy) were retrieved. We also collected data on type of
mutation (i.e., BRCA1 or BRCA2), date of birth, primary
and contralateral BC diagnoses, dates of and findings at
contralateral risk-reducing mastectomy and salpingo-
oophorectomy, and dates of disease recurrence and death or
date of last follow-up if no event occurred.
Statistical analysis
The primary endpoint was the development of CBC
defined as the occurrence of carcinoma in situ or invasive
BC in the contralateral breast at least 3 months after pri-
mary BC diagnosis and no signs of metastatic disease. CBC
diagnosis within 3 months was considered as synchronous
bilateral BC and assumed to be unrelated to the delivery of
radiotherapy for the first BC [3–5]. For this reason, patients
with less than 3 months of follow-up were excluded.
For comparisons of patient, tumor, and treatment char-
acteristics between subgroups, we used Pearson’s v2 tests.
Differences in age at primary BC diagnosis and follow-up
time were analyzed using the Wilcoxon rank-sum test
(Mann–Whitney).
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In the Cox analyses, we applied left truncation of
analysis time and so considered outcome data from
prospective follow-up only. Hereby, we aimed to correct
for potential selection bias, possibly arising due to inclu-
sion of patients undergoing genetic testing after primary
BC or CBC diagnosis [17, 18]. Censoring events were
ipsilateral BC recurrence for which radiotherapy or sys-
temic therapy was applied, distant metastasis, contralateral
risk-reducing mastectomy, other (non-breast) invasive
cancer for which radiotherapy or systemic therapy was
applied, death, and loss to follow up.
We estimated hazard ratios (HRs) and 95 % confidence
intervals (CIs) for radiotherapy (after lumpectomy vs. after
mastectomy vs. none), adjuvant chemotherapy (yes vs no),
adjuvant endocrine therapy (yes vs. no), salpingo-
oophorectomy (treated as time-dependent variable), age at
primary BC, and BRCA mutation type (BRCA1 vs. BRCA2)
using Cox regression in univariate and multivariate anal-
yses. The cumulative 5-, 10-, and 15-year risks of CBC
were calculated using Kaplan–Meier analysis including
only patients who underwent DNA testing for BRCA1/2
mutation before the diagnosis of CBC, to correct for
potential selection bias.
Analyses were performed for the total group and for
patients younger than 40 years at primary BC, as it has
been previously reported that younger patients are more
susceptible for radiation-induced BC [3–6].
The proportion of patients undergoing different locore-
gional treatments over time, including breast-conserving
treatment and mastectomy with or without radiotherapy,
was estimated with a regression line of best fit and 95 % CI
based on the proportion per year. The same was performed
for the proportion of patients undergoing contralateral
prophylactic mastectomy over time. For statistical analysis
STATA, version 13.0, was used. For computing the figures,
R version 3.2.2 (released on 2015-08-14) and the package
GGplot version 1.0.1. were used.
Results
A total of 691 BRCA1/2-associated BC patients, consisting
of 517 BRCA1 and 174 BRCA2 mutation carriers, were
eligible for data analysis (Tables 1, 2). Median time of
follow-up of the entire cohort was 8.6 years with a range
from 0.3 to 34.3 years. A total of 439 patients were treated
with radiotherapy either after lumpectomy (n = 349) or
after mastectomy (n = 85). A total of 325 patients were
younger than 40 years at primary BC diagnosis (Table 2).
Further details on patient, tumor, and treatment character-
istics are presented in Tables 1 and 2.
Of all patients, 161 (23 %) developed CBC, of whom 87
were younger than 40 years at BC onset. The cumulative
5-, 10-, and 15-year risks of CBC for the total cohort were
8, 19, and 32 %, respectively. Among the patients younger
than 40 years, the cumulative 5-, 10-, and 15-year CBC
risks were 11, 32, and 40 %, respectively. Cumulative risks
for age- and BRCA-specific subgroups suggest a higher
cumulative risk for BRCA1-associated patients compared
to BRCA2-associated patients (Table 3). Median time
interval between primary BC and CBC was 4.8 years
(range 0.5–29.0) for the entire cohort and 5.5 years (range
0.5–29.0 years) for patients diagnosed before the age of 40.
Left truncation was applied to correct for survival bias that
may occur in studies with patient recruitment at a variable
time after diagnosis (see statistical analysis). Consequently, a
considerable number of patients did not contribute person-
time to the prospective follow-up, leaving 418 patients for the
main analyses. In univariate analysis, the risk of CBC was
increased in patients younger than 40 years compared to those
older than 40 years at primary BC (HR 2.42, 95 % CI
1.34–4.38). Furthermore, mutation carriership of BRCA1was
associatedwith increased risk of CBC as compared toBRCA2
mutation carriership (HR 2.32, 95 % CI 0.98–5.51). Both
chemotherapy and endocrine therapy were significantly
associated with a decreased risk of CBC (HR 0.45, 95 % CI
0.25–0.81 andHR0.27, 95 %CI 0.08–0.86, respectively). For
salpingo-oophorectomy, no association with CBC risk was
found (HR 0.73, 95 % CI 0.37–1.43) (Table 4).
No deleterious effect of radiotherapy for primary BC,
either after lumpectomy or after mastectomy, on CBC risk
was found for the entire population (HR 0.84, 95 % CI
0.46–1.55 and HR 0.62, 95 % CI 0.17–2.23, respectively)
(Table 4). Adjusting for age, adjuvant chemotherapy,
adjuvant endocrine therapy, and type of BRCA mutation in
a multivariate analysis still showed no association of
radiotherapy on CBC risk (HR 0.74, 95 % CI 0.40–1.37
and HR 0.96, 95 % CI 0.23–3.97, respectively).
Subgroup analyses of patient younger than 40 years
at BC onset
Also in the subgroup of patients younger than 40 years at
primary BC diagnosis, no effect of radiotherapy for pri-
mary BC, either after lumpectomy or after mastectomy, on
CBC risk was found in univariate analysis (n = 211; HR
1.41, 95 % CI 0.62–3.23 and HR 0.94, 95 % CI 0.18–4.86,
respectively), and this was maintained in multivariate
analysis (HR 1.53, 95 % CI 0.22–10.51 and HR 0.97, 95 %
CI 0.41–2.30, respectively) (Fig. 1; Table 4). Median time
interval between primary BC and CBC diagnoses was not
significantly different between those treated with radio-
therapy for primary BC compared to those patients not
receiving radiotherapy (5.5 vs. 4.9 years, p = 0.88).
During follow-up, the number of patients at risk sub-
stantially decreased because a large proportion of patients
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n (%) n (%) n (%) n (%)
Age at primary BC
\30 years 55 (8.0) 29 (8.3) 19 (7.5) 7 (8.2) 0.943
30–34 years 115 (16.6) 59 (16.9) 39 (15.5) 15 (17.0)
35–39 years 155 (22.4) 78 (22.3) 57 (22.6) 20 (23.5)
40–44 years 129 (18.7) 64 (18.3) 49 (19.4) 16 (18.8)
45–50 years 100 (14.5) 48 (13.8 35 (13.9) 16 (18.8)
[50 years 137 (19.8) 71 (20.3) 53 (21.0) 11 (12.9)
Mutation status
BRCA1 517 (74.8) 277 (79.4) 186 (73.8) 50 (58.8) \0.001
BRCA2 174 (25.2) 72 (20.6) 66 (26.2) 35 (41.2)
Period of primary BC
1980–1989 105 (15.2) 64 (18.3) 27 (10.7) 14 (16.5) 0.017
1990–1999 256 (37.1) 139 (39.8) 101 (35.3) 27 (31.8)
2000–2013 330 (47.8) 146 (41.8) 164 (54.0) 44 (51.8)
Tumor stage
Tis 26 (4.0) 14 (4.1) 12 (5.2) 0 \0.001
T1 364 (56.0) 209 (61.8) 130 (56.5) 25 (30.9)
T2 227 (34.9) 114 (33.7) 80 (34.8) 32 (39.5)
T3 25 (3.9) 0 7 (3.0) 18 (22.2)
T4 8 (1.2) 1 (0.3) 1 (0.4) 6 (7.4)
Unknown 41 11 22 4
Nodal status
N0 424 (64.3) 241 (71.9) 169 (70.1) 13 (16.0) \0.001
N1–3 235 (35.7) 94 (28.1) 72 (29.9) 68 (84.0)
Unknown 32 14 11 4
Histological grade
Grade 1 17 (3.3) 8 (3.1) 7 (3.6) 2 (3.0) 0.988
Grade 2 106 (20.4) 54 (21.0) 37 (19.2) 14 (20.9)
Grade 3 396 (76.3) 195 (75.9) 149 (77.2) 51 (76.1)
Unknown 172 92 59 18
Hormone receptor status
Positive 227 (39.5) 108 (37.8) 80 (37.9) 39 (50.0) 0.124
Negative 348 (60.5) 178 (62.2) 131 (62.1) 39 (50.0)
Unknown 116 63 41 7
HER2 status
Positive 17 (6.7) 9 (8.1) 5 (5.2) 3 (7.5) 0.646
Negative 236 (93.3) 101 (91.8) 95 (94.8) 37 (92.5)
Unknown 438 239 152 45
(Contralateral) risk-reducing mastectomy
No 424 (64.5) 243 (73.0) 127 (51.8) 54 (68.4) \0.001
Yes 233 (35.5) 90 (27.0) 118 (46.2) 25 (31.7)
Unknown 34 16 7 6
Salpingo-oophorectomy
No 259 (41.2) 135 (42.5) 87 (38.2) 35 (44.3) 0.499
Yes 370 (58.8) 183 (57.5) 141 (61.8) 44 (55.7)
Unknown 62 31 24 6
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were censored as they underwent a contralateral risk-re-
ducing mastectomy, developed a BC recurrence or a sec-
ond non-breast malignancy. In the group younger than
40 years at BC onset, 165 of 325 patients (51 %) were
censored in the first 10 years of follow-up because of these
three reasons (Fig. 2). Furthermore, since a large propor-
tion of patients had less than 10 years of follow-up time,
only 29 and 14 patients were available for the prospective
analyses after 10 and 15 years of follow-up in this age
group, respectively.
Treatment choices over time
Over the past decades, the proportion of patients at risk for
radiation-induced CBC changed substantially as a result of
an increased rate of mastectomy without radiotherapy
instead of breast-conserving therapy for primary breast
cancer, and an increased rate of contralateral risk-reducing
mastectomy (Figs. 3, 4). For example, patients aged
younger than 40 years at diagnosis more often opted for
mastectomy without radiotherapy instead of breast-con-
serving therapy in 2010 (reaching 50 %), compared to less
than 30 % in 1995. The proportion of patients receiving
radiotherapy following mastectomy was relatively
stable over time being around 10–15 % (Fig. 3). Since
2010, more than 60 % of patients younger than 40 years at
primary diagnosis opted for contralateral risk-reducing
mastectomy, after primary breast cancer treatment, which
was less than 40 % in 1995 (Fig. 4).
Discussion and conclusion
The risk of CBC among BC patients with a BRCA1/2
mutation is high, especially for younger patients. An
association between adjuvant radiotherapy and the
development of CBC in BRCA1/2-associated BC patients
was not observed, neither in the entire cohort, nor in the
subgroup of patients younger than 40 years at primary
diagnosis. We found in this study that during follow-up the
number of patients at risk for developing CBC substantially
decreased due to either contralateral risk-reducing mas-
tectomy or BC recurrence (26 and 14 %, respectively,
within the first 5 years after primary BC among patients
younger than 40 years). As a consequence, the number of
patients at risk after 10 and 15 years of follow-up was too
small to definitively exclude harmful effects of radiother-
apy on the development of CBC among young BRCA1/2
mutation carriers.
A few other studies also reported on CBC risk in
BRCA1/2-associated BC patients treated with adjuvant
radiotherapy compared to patients not treated with radio-
therapy [13–15], and did not find an increased risk of CBC
associated with adjuvant radiotherapy either. In the two
multi-center retrospective cohort studies of breast cancer
patients attending high-risk clinics [13, 14], the numbers of
young BRCA1/2 mutation carriers and follow-up periods
were comparable to our study (145 out of 655 patients
younger than 35 years with a median follow-up of 8 years
in the study of Pierce et al. [13], and 357 out of 810
patients younger than 40 years with a median follow-up of
11 years in the study of Metcalfe et al. [14]). However,
subgroup analyses among these younger patients were not
reported. Bernstein performed a nested case–control study
within the WECARE study (Women’s Environmental
Cancer and Radiation Epidemiology Study), which is a
population-based study of patients with metachronous CBC
[15], but again no results of subgroup analysis in younger
patients were shown.
The main limitation of our study regarding the impact of
radiotherapy on the CBC risk is the small number of











n (%) n (%) n (%) n (%)
(Neo-) adjuvant chemotherapy
No 319 (46.6) 176 (51.0) 109 (43.6) 30 (35.7) 0.022
Yes 365 (53.4) 169 (49.0) 141 (56.4) 54 (64.3)
Unknown 7 4 2 1
Adjuvant endocrine therapy
No 555 (81.1) 300 (87.2) 203 (81.2) 48 (56.5) \0.001
Yes 129 (18.9) 44 (12.8) 47 (18.9) 37 (43.5)
Unknown 7 5 2 0
RT radiotherapy; BC breast cancer
* Data on type of surgery (either lumpectomy or mastectomy) were missing in 5 patients who were treated with radiotherapy
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n (%) n (%) n (%) n (%)
Age at primary BC
\30 years 55 (16.9) 29 (17.5) 19 (16.5) 7 (16.7) 0.996
30–34 years 115 (35.4) 59 (35.5) 39 (33.9) 15 (35.7)
35–39 years 155 (47.7) 78 (47.0) 57 (49.6) 20 (47.6)
Mutation status
BRCA1 261 (80.3) 143 (86.1) 89 (77.4) 27 (64.3) 0.004
BRCA2 64 (19.7) 23 (13.9) 26 (22.6) 15 (35.7)
Period of primary BC
1980–1989 43 (13.2) 33 (19.9) 5 (4.4) 5 (11.9) \0.001
1990–1999 114 (35.1) 68 (41.0) 35 (30.4) 10 (23.8)
2000–2013 168 (51.7) 65 (39.2) 75 (65.2) 27 (64.3)
Tumor stage
Tis 9 (2.9) 4 (2.6) 5 (4.5) 0 \0.001
T1 179 (58.5) 95 (60.5) 70 (63.6) 14 (35.9)
T2 103 (33.7) 57 (36.3) 31 (28.2) 15 (38.5)
T3 8 (2.6) 0 3 (2.7) 5 (12.8)
T4 7 (2.3) 1 (0.6) 1 (0.9) 5 (12.8)
Unknown 19 9 5 3
Nodal status
N0 206 (66.0) 120 (74.5) 78 (70.3) 7 (17.9) \0.001
N1–3 106 (34.0) 41 (25.5) 33 (29.7) 32 (82.1)
Unknown 13 5 4 3
Histological grade
Grade 1 6 (2.5) 2 (1.7) 2 (2.1) 2 (6.5) 0.561
Grade 2 45 (18.4) 21 (17.7) 17 (18.1) 7 (22.6)
Grade 3 193 (79.1) 96 (80.7) 75 (79.8) 22 (71.0)
Unknown 81 47 21 11
Hormone receptor status
Positive 93 (33.1) 41 (29.5) 31 (30.7) 21 (52.5) 0.020
Negative 188 (66.9) 98 (70.5) 70 (69.3) 19 (47.5)
Unknown 44 27 14 2
HER2 status
Positive 10 (7.6) 4 (7.8) 3 (5.5) 3 (12.0) 0.592
Negative 122 (92.4) 47 (92.2) 52 (94.5) 22 (88.0)
Unknown 193 115 60 17
(Neo-) adjuvant chemotherapy
No 125 (38.9) 75 (45.7) 33 (28.9) 16 (39.0) 0.019
Yes 196 (61.1) 89 (54.3) 81 (71.1) 25 (61.0)
Unknown 4 2 1 1
Adjuvant endocrine therapy
No 262 (81.4) 148 (90.2) 90 (78.9) 22 (52.4) \0.001
Yes 60 (18.6) 16 (9.8) 24 (21.1) 20 (47.6)
Unknown 3 0 1 0
Contralateral risk-reducing mastectomy
No 174 (55.8) 105 (66.0) 46 (41.1) 23 (56.1) \0.001
Yes 138 (44.2) 54 (34.0) 66 (58.9) 18 (43.9)
Unknown 13 7 3 1
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studies including sporadic patients suggest that a minimal
latency period of 10–15 years is needed to develop radia-
tion-induced BC [19, 20]. It is, however, not known whe-
ther the latency period between exposure and development
of a radiation-induced malignancy is similar for BRCA1/2
mutation carriers compared to sporadic patients. Even, if
the latency period in BRCA1/2 mutation carriers is shorter,
the number of patients at risk for CBC in our study group
was too small to make definitive conclusions, especially
since a large proportion of patients were already censored
in the first 5 years. Given the number of events in patients
younger than 40 years at primary BC diagnosis, our study
had 80 % power to find an HR of at least 2.8 for adjuvant
radiotherapy to be associated with increased risk of CBC.
In our total cohort, the 10-year cumulative risk of CBC
in BRCA1/2 mutation carriers was 19 %, while in the
subgroup of patients younger than 40 years at BC onset this
risk was 32 %. These risks are comparable to the risks
reported in other studies [14, 21, 22]. Furthermore, the
CBC risk was higher in BRCA1 compared to BRCA2
mutation carriers. Both the increased risk in younger
patients and the increased risk in BRCA1- compared to
BRCA2-associated BC patients have been described in
other studies [14, 21–23]. Additionally, in our cohort
adjuvant systemic therapy for primary BC, applying for
both endocrine therapy and chemotherapy, was associated
with a decreased risk of CBC. This effect, however, was
only significant in the entire cohort and not in the subgroup
of younger patients. Since the HRs were similar, this might
be due to the lack of statistical power. The risk-reductive
effect of adjuvant endocrine therapy on CBC risk in
BRCA1/2 mutation carriers has been reported in previous
studies [14, 24, 25]. Regarding chemotherapy, three studies
have investigated the association between chemotherapy
and CBC [14, 23, 26], whereby only Reding et al. found a
significant association with a relative risk of 0.5. Although
this latter association is biologically not totally clear, fur-
ther research is certainly warranted. We did not find any
impact of salpingo-oophorectomy on CBC risk, which is in
contrast with previous reports [27, 28], but is in line with
more recent literature [29].
In our cohort, we found a growing preference over time
for mastectomy without radiotherapy instead of breast-
conserving therapy including radiotherapy. At the same
time, the rate of contralateral risk-reducing mastectomy
after primary breast cancer treatment has increased.
Important reasons for the shift toward ablative breast sur-
gery might be the improvements in and availability of
(direct) breast reconstructive options, the increased
awareness of the magnitude of the CBC risk and distress of
screening, and the wish to avoid another treatment session
for a second primary BC. Finally, the important findings of
Heemskerk et al. showing that contralateral risk-reducing
mastectomy improves survival, mainly in younger patients
and those with favorable primary tumor characteristics











n (%) n (%) n (%) n (%)
Salpingo-oophorectomy
No 128 (42.8) 66 (43.7) 43 (40.6) 18 (45.0) 0.825
Yes 171 (57.2) 85 (56.3) 63 (59.4) 22 (55.0)
Unknown 26 15 9 2
RT radiotherapy; BC breast cancer
* Data on type of surgery (either lumpectomy or mastectomy) were missing in 2 patients who were treated with radiotherapy
Table 3 Cumulative 5-, 10-, and 15-year risks of contralateral breast cancer
Years after diagnosis Overall %
(n at risk)
BRCA1 mutation
% (n at risk)
BRCA2 mutation
% (n at risk)
Age\ 40 % (n at risk) Age C 40 % (n at risk)
5 8 (198) 9 (140) 5 (58) 11 (86) 6 (112)
10 19 (98) 21 (75) 15 (23) 32 (39) 10 (59)
15 32 (47) 35 (37) 15 (10) 40 (17) 23 (30)
Cumulative 5-, 10-, and 15-year risks of contralateral breast cancer in different subgroups of breast cancer patients (BRCA1 mutation carriers vs.
BRCA2 mutation carriers and age at primary breast cancer\40 vs. C40 years). Only those patients who underwent DNA testing for BRCA1/2
mutation before the diagnosis of contralateral breast cancer were included
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patients opting for mastectomy without radiotherapy and
contralateral risk-reducing mastectomy after primary breast
cancer diagnosis in the nearby future.
These trends in locoregional treatments eventually
decreased the proportion of patients at risk for radiation-
induced CBC over the past few decades. Nevertheless, the
question whether adjuvant radiotherapy has deleterious
effect on CBC risk still remains clinically important for a
significant number of patients, who want to conserve their
(ipsilateral and) contralateral breast. Moreover, in the
nearby future a larger proportion of patients potentially
might opt for breast-conserving treatment and abstain from
contralateral risk-reducing mastectomy, due to an increased
use of endocrine therapy as chemoprevention, improved
diagnostic imaging techniques for screening, and improved
effectiveness of adjuvant systemic therapy (for example, in
combination with PARP inhibitors) [31–33].
In the current study, we could not find an association
between radiotherapy for primary BC and risk of CBC in
Table 4 Univariate and multivariate hazard ratios for risk of contralateral breast cancer associated with selected factors
Overall Age\ 40 years
Univariate analyses
Number of patients: n = 418
Person years: 1105 years
HR (95 % CI)
Univariate analyses
Number of patients: n = 211
Person years: 467 years
HR (95 % CI)
Multivariate analysis*
Number of patients: n = 211
Person years: 467 years
HR (95 % CI)
Age at primary breast cancer
\40 years 2.42 (1.34–4.38)
C40 years 1
Age at primary breast cancer
Continuous 0.94 (0.90–0.97) 0.93 (0.85–1.01) 0.96 (0.88–1.06)
BRCA mutation
BRCA1 2.32 (0.98–5.51) 3.52 (0.83–14.99) 2.33 (0.51–10.73)
BRCA2 1 1 1
Chemotherapy
No 1 1 1
Yes 0.45 (0.25–0.81) 0.51 (0.24–1.09) 0.52 (0.24–1.14)
Endocrine therapy
No 1 1 1
Yes 0.27 (0.08–0.86) 0.24 (0.06–1.02) 0.25 (0.05–1.23)
Salpingo-oophorectomy (time-dependent)
No 1 1
Yes 0.73 (0.37–1.43) 1.22 (0.53–2.81)
Radiotherapy
No radiotherapy after mastectomy 1 1 1
Radiotherapy after mastectomy 0.62 (0.17–2.23) 0.94 (0.18–4.86) 0.97 (0.41–2.30)
Radiotherapy after lumpectomy 0.84 (0.46–1.55) 1.41 (0.62–3.23) 1.53 (0.22–10.51)
HR Hazard ratio
* The following variables were incorporated in the multivariate model: age at primary breast cancer (continuous variable), type of BRCA
mutation (BRCA1 vs. BRCA2), adjuvant chemotherapy (yes vs. no), adjuvant endocrine therapy (yes vs. no), and radiotherapy (no radiotherapy
after mastectomy vs. radiotherapy after mastectomy and vs. radiotherapy after lumpectomy)
Fig. 1 Kaplan–Meier estimates of the contralateral breast cancer
(CBC) risk in BRCA1/2 mutation carriers, younger than 40 years of
age at primary BC diagnosis. For this analysis, left truncation of
analysis time at the DNA test date was applied, to correct for survival
bias. Patients treated with radiotherapy (either after lumpectomy or
after mastectomy) were compared to those not treated with radio-
therapy at primary BC diagnosis
178 Breast Cancer Res Treat (2015) 154:171–180
123
(young) BRCA1/2 mutation carriers compared to sporadic
patients; however, the number of patients at risk after 10
and 15 years of follow-up was too small to definitively
exclude harmful effects of adjuvant radiotherapy. An
increase in the percentage of young patients with BRCA1/
2-associated breast cancer choosing for conserving their
(ipsilateral and) contralateral breast is not unlikely.
Therefore, future research in larger study populations with
minimal follow-up of 10 years is needed to achieve a better
understanding of the true effect of radiotherapy on the CBC
risk in BRCA1/2-associated BC patients. This will only be
possible by combining study populations through collabo-
rative efforts on a national or even international level.
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Fig. 2 Cumulative frequency
of contralateral breast cancer
(CBC) or reasons for censoring
event at study start and after 5,
10, 15, and 20 years of follow-
up in all included patients who
were younger than 40 years of
age at primary breast cancer
diagnosis. Recurrence includes
both ipsilateral recurrence, a
second ipsilateral primary
tumor, and metastatic disease.
(C)RRM = (contralateral) risk-
reducing mastectomy. End of
FU (follow-up) comprises
patients who did not reach the
primary endpoint or other
censoring event at data cut-off
or were lost to follow up
Fig. 3 Distribution of the choice of local therapy at primary breast
cancer diagnosis by year of diagnosis among patients younger than
40 years of age with a BRCA1 or BRCA2 mutation. Regression line of
best fit and estimate of 95 % confidence interval (gray). RT
Radiotherapy
Fig. 4 Proportion of patients with a BRCA1 or BRCA2 mutation and
breast cancer diagnosis below the age of 40 opting for contralateral
(or bilateral) risk-reducing mastectomy (either at primary breast
cancer treatment or within the years after primary breast cancer) by
year of breast cancer diagnosis. Regression line of best fit and
estimate of 95 % confidence interval (gray)
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